Renal involvement in systemic lupus erythematosus (SLE) is an important cause of morbidity and mortality, reaching a prevalence of 39% during the course of the disease. Currently, the therapy for severe lupus nephritis is based on the use of high-dose corticosteroids and immunosuppressive drugs, being traditionally cyclophosphamide the most frequently used agent. Recent studies have demonstrate...

Neuropsychiatric abnormalities frequently occur in patients with systemic lupus erythematosus, affecting as many as 14-75% of people with this disease. High-dose steroid with or without anticoagulation is the mainstay of treatment in neuropsychiatric systemic lupus erythematosus (NPSLE). Use of mycophenolate as a steroid sparing drug may be a potential alternative agent in the therapy of NPLE, ...

1 of 2 DESCRIPTION A 25-year-old female with mixed connective tissue disease (MCTD) complicated by scleroderma renal crisis presented with a 2-week history of profuse, watery diarrhoea that persisted through the night and with fasting. She has been maintained on mycophenolate mofetil (MMF) at 1000 mg/day for 1 year for her MCTD. The patient reported no recent travel or similar illness in her ho...

Lymphoid interstitial pneumonia (LIP) is a poorly understood lymphoproliferative disorder that can be idiopathic or associated with different conditions. LIP is considered to be steroid responsive. However, its response is mainly unpredictable with a high mortality rate. Here we describe a rare case of idiopathic LIP that shows clinical improvement to Mycophenolate Mofetil after intolerable sid...

Chronic Myelogenic Leukemia (CML) is a rare malignant disorder after solid organ transplantation, especially in renal transplant recipients. Imatinib Mesylate is currently approved as first line treatment of CML. Most reports on CML are from kidney recipients who received azathioprine  in combination with cyclosporine and prednisolone as immunosuppressive therapy. We report a case with CML who ...

Background: Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is used during nonmyeloablative and reduced-intensity conditioning haematopoetic cell transplantation (HCT) to improve engraftment and reduce graft versus host disease (GVHD). However, information about MPA pharmacokinetics is sparse in this context and its use is still empirical.

A 21-year-old female presenting linear IgA and IgG disease initially responded well to dapsone therapy. However, the treatment with dapsone was withdrawn due to severe anemia induced by malaria, which led to worsening of the clinical picture. Although prednisone and methylprednisolone were tried, the patient responded only to the association of dapsone and mycophenolate mofetil.